Hyperfine (HYPR) Capital Expenditures (QoQ) (2021 - 2026)
Hyperfine (HYPR) Capital Expenditures (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Hyperfine | 90.12 Mn | 45.35 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.60% |
| Mar 31, 2026 | 9.52% |
| Dec 31, 2025 | -51.54% |
| Sep 30, 2025 | -88.39% |
| Jun 30, 2025 | 975.00% |
| Mar 31, 2025 | 85.71% |
| Dec 31, 2024 | -446.34% |
| Sep 30, 2024 | -2,242.86% |
| Jun 30, 2024 | -100.94% |
| Mar 31, 2024 | 104.97% |
| Dec 31, 2023 | 312.94% |
| Sep 30, 2023 | -2,025.00% |
| Jun 30, 2023 | -122.22% |
| Mar 31, 2023 | -82.44% |
| Dec 31, 2022 | -57.20% |
| Sep 30, 2022 | 520.18% |
| Jun 30, 2022 | -283.87% |
| Mar 31, 2022 | -89.44% |
| Dec 31, 2021 | -1.18% |
| Sep 30, 2021 | 1,663.16% |